ReviewDrug metabolism and disposition: the biological fate of chemicals2026
Endogenous biomarkers for assessing CYP3A4 and CYP2D6 activity: A critical review.
Review in Drug metabolism and disposition: the biological fate of chemicals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytochrome P450 (P450) enzymes play an important role in the biotransformation of both exogenous and endogenous compounds. Variability in P450 expression and activity impacts drug-metabolizing capacity and contributes to interindividual differences in drug exposure and therapeutic outcomes. Exogenous probe substrates have traditionally been used to assess the in vivo P450 enzyme activity. However, their application can be limited in vulnerable populations such as pregnancy, transplantation, pediatrics, and elderly. Endogenous biomarkers have emerged as minimally invasive potential alternatives that can reflect the P450 enzyme activity under different physiologic and clinical conditions. In this minireview, we critically examine various endogenous biomarkers that have been proposed to assess P450 activity, with specific emphasis on CYP3A4 and also discuss emerging endogenous biomarkers of CYP2D6 activity. We summarize mechanistic and translational applicability and regulatory guidelines in predicting drug-drug interactions and use of mathematical modeling and simulation approaches to validate the biomarkers. Additionally, we discuss the potential role of metabolomics in endogenous biomarker discovery and outline current limitations and future directions underscoring the utility of endogenous biomarkers in drug metabolism and drug disposition in patients. SIGNIFICANCE STATEMENT: Endogenous biomarkers offer a minimally invasive mechanistic approach for assessing in vivo P450 activity and complement traditional drug probe-based phenotyping strategies. This minireview evaluates the currently used endogenous biomarkers of CYP3A4 and emerging candidates for CYP2D6, highlighting their translational advances, limitations, and potential integration with metabolomics and model-informed drug development for drug disposition and interaction assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.